Baljash S. Cheema
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Baljash S. Cheema has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alireza Khoddam
Feinberg Cardiovascular and Renal Research Institute
1 shared publication - Andrew Decker
Feinberg Cardiovascular and Renal Research Institute
1 shared publication - Anthony Kalousdian
Feinberg Cardiovascular and Renal Research Institute
1 shared publication - Arun Sivakumar
Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
1 shared publication - Bedirhan Boztepe
Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
1 shared publication - Benjamin W. Zywicki
Feinberg Cardiovascular and Renal Research Institute
1 shared publication
Latest Publications
- Open Access
- 30 September 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (23)
Plasminogen activator inhibitor 1 promotes aortic aging–like pathophysiology in humans and mice
Plasminogen activator inhibitor 1 (PAI-1), encoded by SERPINE1 , contributes to age-related cardiovascular disease (CVD) and other aging-related pathologies. Humans with a heterozygous loss-of-function SERPINE1 variant exhibit protection against aging and cardiometabolic dysfunction. We engineered a mouse model mimicking the human mutation ( Serpine1 TA700/+ ) and compared cardiovascular responses with WT littermates. Serpine1 TA700/+ mice lived 17% longer than did littermate control mice. Under l-N G -nitro-arginine methyl ester–induced (l-NAME–induced) vascular stress, Serpine1 TA700/+ mice exhibited diminished pulse wave velocity (PWV), lower systolic blood pressure (SBP), and preserved left ventricular diastolic function compared with controls. Conversely, PAI-1–overexpressing mice had measurements indicating accelerated cardiovascular aging. Single-cell transcriptomics of Serpine1 TA700/+ aortas revealed a vascular-protective mechanism with downregulation of the extracellular matrix regulators Ccn1 and Itgb1 . Serpine1 TA700/+ aortas were also enriched in a cluster of smooth muscle cells that exhibited plasticity. Finally, PAI-1 pharmacological inhibition normalized SBP and reversed l-NAME–induced PWV elevation. These findings demonstrate that PAI-1 reduction protects against cardiovascular aging-related phenotypes, while PAI-1 excess promotes vascular pathological changes. Taken together, PAI-1 inhibition represents a promising strategy to mitigate age-related CVD.
- 30 September 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (23)
Open AccessPlasminogen activator inhibitor 1 promotes aortic aging–like pathophysiology in humans and mice
Plasminogen activator inhibitor 1 (PAI-1), encoded by SERPINE1 , contributes to age-related cardiovascular disease (CVD) and other aging-related pathologies. Humans with a heterozygous loss-of-function SERPINE1 variant exhibit protection against aging and cardiometabolic dysfunction. We engineered a mouse model mimicking the human mutation ( Serpine1 TA700/+ ) and compared cardiovascular responses with WT littermates. Serpine1 TA700/+ mice lived 17% longer than did littermate control mice. Under l-N G -nitro-arginine methyl ester–induced (l-NAME–induced) vascular stress, Serpine1 TA700/+ mice exhibited diminished pulse wave velocity (PWV), lower systolic blood pressure (SBP), and preserved left ventricular diastolic function compared with controls. Conversely, PAI-1–overexpressing mice had measurements indicating accelerated cardiovascular aging. Single-cell transcriptomics of Serpine1 TA700/+ aortas revealed a vascular-protective mechanism with downregulation of the extracellular matrix regulators Ccn1 and Itgb1 . Serpine1 TA700/+ aortas were also enriched in a cluster of smooth muscle cells that exhibited plasticity. Finally, PAI-1 pharmacological inhibition normalized SBP and reversed l-NAME–induced PWV elevation. These findings demonstrate that PAI-1 reduction protects against cardiovascular aging-related phenotypes, while PAI-1 excess promotes vascular pathological changes. Taken together, PAI-1 inhibition represents a promising strategy to mitigate age-related CVD.